Skye Bioscience, Inc. Common Stock (SKYE) earnings · next report Nov 9, 2026
Next report
Mon, Nov 9, 2026
After the close · In 5 days
Quarter ended Sep 2026
- EPS consensus
- −$1.12 Range −$1.12 – −$1.121 analystsYear ago −$2.59
- Revenue consensus
- $0 Range $0 – $05 analysts
EPS estimate trend
- 90 days ago−$2.01
- 60 days ago−$2.01
- 30 days ago−$2.01
- 7 days ago−$1.12
- Now−$1.12
Consensus +44.4% over 90 days. Last 30 days: 0 up, 0 down revisions.
Date and consensus: EODHD earnings calendar and estimates, refreshed every 6 hours. “Confirmed” means the provider lists the report session, which it sets once the company announces; “Estimated” is the provider’s expected date.
Follow SKYE into its report
Save it to a free watchlist (no card). Alerts when the date moves or results land are part of Pro.
Earnings move
- Options price in (Nov 9)
- — No options snapshot for this report yet (taken daily in the 7 days before a report, for stocks with listed options).
- Average move after earnings
- ±7.3% Absolute close-to-close move, 2 reports
Options-implied move: the at-the-money straddle (call + put) on the first expiry after the report, divided by the stock’s close, from EODHD end-of-day option chains. It is what the options market prices as the absolute move to that expiry, not a forecast of direction. Move: close before the news → close after it (before the open: prior close → report-day close; after the close: report-day close → next close), adjusted for splits and dividends, from EODHD end-of-day prices. Reports with an unannounced time are not averaged: both candidate moves are stored instead. Per-report moves, gaps, moves vs SPY and the sector, beat/miss asymmetry and implied vs actual are in Lician Pro below.
Latest result
EPSGAAP
−$0.27
vs −$0.29 est. +6.9%
GAAP diluted EPS, SEC 10-Q
Revenue
—
No revenue consensus stored
EPS actuals are checked against the SEC filing and the company’s earnings press release (8-K EX-99.1). A company that reports only GAAP EPS is graded on its SEC diluted EPS; one that reports adjusted EPS is graded on the provider’s adjusted figure when the release confirms it. A figure that matches neither is shown as unverified, with no beat or miss. Revenue actuals come from the SEC filing of the same quarter where we have it.
Beat / miss history
- Beat EPS in 1 of 4
- Aug 14, 2026BeatEPS −$0.27GAAP vs −$0.29 +6.9%Rev — vs —
- May 11, 2026In lineEPS −$0.32GAAP vs −$0.32 0.0%Rev — vs —
- Nov 10, 2025In lineEPS −$0.32GAAP vs −$0.32 0.0%Rev — vs —
- Aug 7, 2025MissEPS −$0.44GAAP vs −$0.34 −29.4%Rev — vs —
| Reported | Quarter | EPS est. | EPS actual | Surprise | Revenue est. | Revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | Jun 2026 | −$0.29 | −$0.27GAAP | +6.9% | — | — | — |
| May 11, 2026 | Mar 2026 | −$0.32 | −$0.32GAAP | 0.0% | — | — | — |
| Nov 10, 2025 | Sep 2025 | −$0.32 | −$0.32GAAP | 0.0% | — | — | — |
| Aug 7, 2025 | Jun 2025 | −$0.34 | −$0.44GAAP | −29.4% | — | — | — |
Earnings documents
No earnings 8-K (item 2.02) is stored for this report yet. All SKYE filings: SEC filings.
Documents link to SEC EDGAR. Lician does not publish earnings-call transcripts.
Healthcare peers with similar quant ratings
SKYE among 532 rated Healthcare stocks (Lician quant rating, Nov 4, 2026). How the rating works
- QTTB earnings5.00 · Strong Buy · stock
- AVAH earnings4.99 · Strong Buy · stock
- CDNA earnings4.98 · Strong Buy · stock
- HALO earnings4.97 · Strong Buy · stock
- OSCR earnings4.97 · Strong Buy · stock
- REGN earnings4.95 · Strong Buy · stock
- CON earnings4.94 · Strong Buy · stock
- PACS earnings4.94 · Strong Buy · stock
| Quarter | Revenue | EPS | YoY |
|---|---|---|---|
| Q2 FY26 | — | −$0.27 | — |
| Q1 FY26 | — | −$0.32 | — |
| Q3 FY25 | — | −$0.32 | — |
| Q2 FY25 | — | −$0.44 | — |
Skye Bioscience, Inc. Common Stock (SKYE) is a biotechnology company listed on NASDAQ.
No cached income statement for SKYE yet, so there is no earnings base to recap.
When the next SKYE 8-K Item 2.02 lands, this page should move. Until then the SEC archive is the source.
Period-over-period revenue change is not in cache for SKYE. We will not invent a beat or miss.
Not investment advice. Full SKYE research stays on the stock page; the tape stays on the quote page.
SKYE earnings FAQ
When is SKYE's next earnings date?
Skye Bioscience, Inc. Common Stock (SKYE) is expected to report on Mon, Nov 9, 2026, after the close. The provider lists the session, which it sets once the company announces. Consensus EPS is −$1.12.
Did SKYE beat earnings estimates last quarter?
Yes. On Aug 14, 2026 Skye Bioscience, Inc. Common Stock (SKYE) reported adjusted EPS of −$0.27 against a −$0.29 consensus (+6.9%), a beat.
How often does SKYE beat EPS estimates?
Skye Bioscience, Inc. Common Stock (SKYE) beat the EPS consensus in 4 of its last 9 reported quarters.
Not investment advice.